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594Background: Safe and effective therapies are needed for pediatric patients with psoriasis.Objective: The purpose of this study was to evaluate ustekinumab in patients age 12 to 17 years who had
moderate-to-severe psoriasis.Methods: Patients (n = 110) were randomly assigned to ustekinumab standard dosing (SD; 0.75 mg/kg
[#60 kg], 45 mg [ 60-#100 kg], and 90 mg [ 100 kg]) or half-standard dosing (HSD; 0.375 mg/kg [#60 kg],
22.5 mg [ 60-#100 kg], and 45 mg [ 100 kg]) at weeks 0 and 4 and every 12 weeks or placebo at weeks
0 and 4 with crossover to ustekinumab SD or HSD at week 12. Clinical assessments included the proportion
of patients achieving a Physician’s Global Assessment of cleared/minimal (PGA 0/1), at least 75%
improvement in Psoriasis Area and Severity Index (PASI 75), and at least 90% in PASI (PASI 90). Adverse
events (AEs) were monitored through week 60.Results: At week 12, 67.6% and 69.4% of patients receiving ustekinumab HSD and SD, respectively,
achieved PGA 0/1 versus 5.4% for placebo (P \ .001). Significantly greater proportions receivingMemorial University of Newfoundland, Canadaa; Janssen
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Landells et al 595ustekinumab achieved PASI 75 (HSD, 78.4%; SD, 80.6%; placebo, 10.8%) or PASI 90 (HSD, 54.1%; SD,
61.1%; placebo, 5.4%) at week 12 (P\ .001). Through week 12, 56.8% of placebo patients, 51.4% of HSD
patients, and 44.4% of SD patients reported at least one AE; through week 60, 81.8% reported AEs.Limitations: The study was small relative to adult trials.Conclusions: In this patient population (12e17 years), the standard ustekinumab dose provided
response comparable to that in adults with no unexpected AEs through 1 year. ( J Am Acad Dermatol
2015;73:594-603.)
Key words: adolescent; biologic; children; pediatric; psoriasis; systemic therapy; ustekinumab.CAPSULE SUMMARY
d Few clinical studies of psoriasis therapies
in children are available in the medical
literature.
d Every-12-week dosing with ustekinumab
was beneficial, with no unexpected
adverse events, in treating patients age
12 to 17 years with moderate-to-severe
psoriasis.
d Ustekinumab appears to be a viable
treatment option for moderate-to-severe
plaque psoriasis in the pediatric
adolescent population.INTRODUCTION
Psoriasis can present at
any age, with approximately
one-third of patients having
symptoms before age 20
years.1 Treatment of pediatric
patients is complicated by
limited approved treatments
and the relative paucity
of data from randomized,
controlled trials available for
this population.2,3 Safe, effec-
tive, and convenient thera-
pies are needed for pediatric
patients with moderate-to-
severe psoriasis.
Ustekinumab, a human
monoclonal antibody targeting the p40 subunit of
interleukin-12/23, has proven to be a safe and
effective treatment for moderate-to-severe psoria-
sis in adult patients.4 In the PHOENIX trials,
ustekinumab effectively reduced psoriasis signs
and symptoms in adult patients.5,6 Results of the
CADMUS trial of ustekinumab in adolescent
patients age 12 to 17 years with active psoriasis
are reported here.
METHODS
Eligible patients were age 12 to 17 years, (inclu-
sive), had a diagnosis of moderate-to-severe plaque
psoriasis (ie, baseline Psoriasis Area and Severity
Index [PASI] $12, a Physician’s Global Assessment
[PGA] $3; and $10% body surface area involved
with psoriasis) for $6 months, were candidates for
phototherapy or systemic treatment, or had psoriasis
that was poorly controlled with topical therapy.
The pharmacokinetics of ustekinumab is affected
by bodyweight. Hence, dosing for adult patients with
psoriasis is weight based (45 mg for patients weigh-
ing #100 kg and 90 mg for patients weighing
[100 kg) and administered as subcutaneous injec-
tions at weeks 0 and 4 and every 12 weeks subse-
quently.4 No clinically meaningful effects of age onthe catabolism of immuno-
globulins, including usteki-
numab,7 have been reported
to date. After accounting for
body weight differences, the
pharmacokinetics of usteki-
numab in pediatric patients
in this trial was expected to
be similar to that in adults.
A standard dose (SD) of
0.75 mg/kg was chosen by
adjusting the 45-mg adult
dose by a body weight of
60 kg (45/60 = 0.75 mg/kg)
leading to the following
study dosages: (1) weight-
based dose of 0.75 mg/kg(patients weighing #60 kg), (2) fixed 45-mg
dose (patients weighing [60 to #100 kg), and
(3) fixed 90-mg dose (patients weighing[100 kg).
Additionally, a half-standard dose (HSD) (ie,
0.375 mg/kg for patients weighing #60 kg, 22.5 mg
for patients weighing[60 to#100 kg, and 45 mg for
patients weighing[100 kg) was included to identify
an optimal dose regimen for pediatric patients.
In this phase 3, multicenter, double-blind,
placebo-controlled study, randomization was strati-
fied by investigational site and baseline weight (# or
[60 kg). Treatment was allocated using a minimiza-
tion algorithm with a biased-coin assignment8 via an
interactive voice/web response system. Patients
were randomly assigned (2:2:1:1) to receive
ustekinumab HSD or SD at weeks 0, 4, and 16 and
thereafter every 12 weeks through week 40 or
placebo at weeks 0 and 4, with crossover to either
ustekinumab HSD or SD at weeks 12 and 16 and
every 12 weeks through week 40 (Fig 1). At week 8,
patients with a PASI increase $50% from
baseline were eligible to commence treatment
with moderate-to-high potency topical steroid
preparations through week 12 (early escape).
The protocol was approved by an institutional
review board or ethics committee, and all patients or
Abbreviations used:
AE: adverse event
CDLQI: Children’s Dermatology Life Quality
Index
HRQoL: health-related quality of life
HSD: half-standard dose
PASI: Psoriasis Area and Severity Index
PASI 75: at least 75% improvement in PASI
PASI 90: at least 90% improvement in PASI
PGA: Physician’s Global Assessment
PGA 0/1: PGA of cleared (0) or minimal (1)
SAE: serious adverse event
SD: standard dose
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informed consent/assent before study-related pro-
cedures were performed.
Clinical response was evaluated using the PGA
and PASI.9 Health-related quality of life (HRQoL) was
assessed using the Children’s Dermatology Life
Quality Index (CDLQI).10 The primary endpoint
was the proportion of patients with a PGA 0/1 at
week 12. Major secondary endpoints were the
proportions of patients achieving at least 75%
improvement in PASI (PASI 75) and at least 90%
improvement in PASI (PASI 90) at week 12 and the
change from baseline in CDLQI at week 12.
Assessments were performed through week 52.
Adverse events (AEs) were monitored through
week 60. Serum samples were collected at selected
visits to measure ustekinumab concentrations
and evaluate for the presence of antibodies to
ustekinumab. Antibody-to-ustekinumab status
was determined using a sensitive, drug-tolerant
electrochemiluminescent immunoassay on the
Meso Scale Discovery platform (Gaithersburg, MD).Statistical methods
To maintain an overall type I error rate of 0.05, the
analyses were conducted sequentially in the order of
primary endpoint, then major secondary endpoints
based on Holm’s procedure,11 and were contingent
on at least 1 ustekinumab dose being significantly
different from the placebo group for each endpoint.
Patients who discontinued study treatment
because of an unsatisfactory therapeutic effect or
an AE of worsening psoriasis or used protocol-
prohibited therapies for psoriasis were classified as
nonresponders for dichotomous endpoints or as
zero change for continuous endpoints thereafter.
Patients with missing PGA or PASI at week 12 were
classified as nonresponders. Patients who used a
moderate-to-high potency topical steroid after
entering early escape were considered nonre-
sponders at week 12 for binary endpoints; the lastvalue at or before week 8 was used to impute
continuous endpoints.
Dichotomous endpoints were analyzed using a
Cochran Mantel Haenszel test, with baseline weight
(# or[60 kg) as a stratification factor. Continuous
variables were analyzed using analysis of variance
on the van derWaerden normal scores, with baseline
weight as a binary covariate.
Primary and major secondary PASI analyses
included all randomized patients, and analyses of
CDLQI outcomes included randomly assigned
patients with evaluable measurements; responses
are reported by randomized treatment group. In the
placebo groups, only patients who crossed over to
ustekinumab at week 12 were included in efficacy
summaries after week 12. AEs are reported by actual
treatment received for patients who had received$1
injection of placebo or ustekinumab. All analyses
were performed using SAS software Version 9.2 (SAS
Institute, Cary, NC).
RESULTS
The study was conducted between March 2010
and January 2014 at 36 sites in Canada and Europe. A
total of 110 patients were randomly assigned to
receive ustekinumab SD (n = 36), ustekinumab
HSD (n = 37), or placebo (n = 37; crossover to SD
[n = 18] or HSD [n = 19]) (Fig 2). At week 8, 1 patient
each in the HSD and SD groups entered early escape.
Through week 40, 9 (8.2%) patients discontinued
study agent because of unsatisfactory therapeutic
effect (n = 5), AEs (n = 3), or death (n = 1).
Baseline demographics and disease characteris-
tics were well balanced across the treatment groups
(Table I). Mean age was 15.2 years, with most
patients 15 to 17 years of age (n = 77; 70.0%). Mean
body weight was 65.0 kg; 51 (46.4%) patients
weighed #60 kg, 56 (50.9%) weighed greater than
60 to #100 kg, and 3 (2.7%) weighed greater than
100 kg. Disease activity scores at baseline were
consistent with moderate-to-severe disease; mean
CDLQI (9.6) indicated a moderate effect of psoriasis
on HRQoL.
At week 12, the proportions of patients
achieving PGA 0/1 were significantly greater in
the HSD (67.6%) and SD (69.4%) groups versus
placebo (5.4%; P \ .001 for both dose groups;
Table II). Onset of response was rapid; approxi-
mately one-third of patients in each ustekinumab
group achieved PGA 0/1 at week 4 (the first
postbaseline visit) compared with 1 (2.7%) patient
in the placebo group (Fig 3). Additionally, signif-
icantly greater proportions of patients in the HSD
(32.4%) and SD (47.2%) groups achieved a PGA of
0 at week 12 compared with placebo (2.7%; both
Screening Controlled Period Placebo Crossover and Active Treatment
Ustekinumab Half-Standard Dosage
EE to topical steroids
Follow-up
Weeks -6-0
R
Weeks 0-12
8
Weeks 12-5 Weeks 52-60
Ustekinumab Standard Dosage
EE to topical steroids
8
Placebo
Ustekinumab Half-Standard Dosage
Ustekinumab Standard Dosage
EE to topical steroids
    = Injection visits
Half-Standard = ≤60 kg, 0.375 mg/kg; >60 to ≤100 kg, 22.5 mg; >100 kg, 45 mg
Standard = ≤60 kg, 0.75 mg/kg; >60 to ≤100 kg, 45 mg; >100 kg, 90 mg
Week 0
8
4 8 12 16 20 24 28 32 36 40 44 48 52 60
2
Fig 1. Ustekinumab in adolescent patients with psoriasis. Study schema through week 60.
EE, Early escape; R, randomization.
Week 12
Week 40
110 Patients randomized and treated
Ustekinumab
Standard Dosage
(n = 36)
Ustekinumab
Half-Standard Dosage
(n = 37)
19 Patients
crossed over to 
Half-Standard Dosage 
at week 12
17 Patients completed
study agent 
at week 40
18 Patients completed
study agent 
at week 40
32 Patients completed
study agent 
at week 40
34 Patients completed
study agent 
at week 40
18 Patients
crossed over to 
Standard Dosage 
at week 12
Placebo
(n = 37)
1 Patient entered early
escape at week 8
1 Patient entered early
escape at week 8
2 patients discontinued
study agent due to AEs
2 Patients discontinued
study agent due to
unsatisfactory 
therapeutic effect
5 Patients discontinued 
study agent:
• 1 AE
• 1 Death
• 3 Due to unsatisfactory 
  therapeutic effect
Fig 2. Ustekinumab in adolescent patients with psoriasis. Patient disposition through week 40.
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tions of patients receiving ustekinumab achieved
PASI 75 (HSD, 78.4%; SD, 80.6%; placebo, 10.8%;
P \ .001) or PASI 90 (HSD, 54.1%; SD, 61.1%;
placebo, 5.4%; P \ .001; Table II). Furthermore,
21.6% of patients in the HSD group and 38.9% in
the SD group achieved a PASI score of 0 (cleared)
at week 12 compared with 2.7% in the placebogroup (P = .014 and P \ .001, respectively). The
treatment effect of both the HSD and SD of
ustekinumab through week 12 for patients
#60 kg was consistent with that observed in
patients greater than 60 kg to #100 kg (data not
shown).
In both ustekinumab groups, the proportions of
patients who achieved PGA 0/1, PASI 75, or PASI 90
Table I. Baseline demographics and disease characteristics
Placebo
Ustekinumab
TotalHalf-standard dosage* Standard dosagey Combined
Patients randomized, n 37 37 36 73 110
Males, n (%) 20 (54.1) 18 (48.6) 16 (44.4) 34 (46.6) 54 (49.1)
Age, y
Mean (SD) 15.6 (1.5) 15.1 (1.7) 14.8 (1.7) 14.9 (1.7) 15.2 (1.7)
Body weight, kg
Mean (SD) 64.7 (14.7) 68.2 (24.5) 62.0 (17.1) 65.1 (21.2) 65.0 (19.2)
Race, n (%)
White 34 (91.9) 30 (81.1) 34 (94.4) 64 (87.7) 98 (89.1)
Psoriasis disease duration, y
Mean (SD) 6.2 (5.0) 5.9 (4.0) 5.6 (3.8) 5.7 (3.9) 5.9 (4.3)
Age at diagnosis, y
Mean (SD) 9.5 (5.0) 9.2 (4.5) 9.3 (4.3) 9.2 (4.4) 9.3 (4.6)
BSA, %
Mean (SD) 27.4 (16.4) 33.6 (21.4) 31.9 (23.2) 32.7 (22.1) 30.9 (20.5)
PASI score (0-72)
Mean (SD) 20.8 (8.0) 21.0 (8.5) 21.7 (10.4) 21.3 (9.4) 21.1 (8.9)
PGA score, n (%)
Marked or severe ($4) 15 (40.5) 15 (40.5) 12 (33.3) 27 (37.0) 42 (38.2)
CDLQI (0-30), n 33 36 32 68 101
Mean (SD) 9.1 (6.4) 9.4 (6.5) 10.3 (6.6) 9.8 (6.5) 9.6 (6.5)
Prior medications for psoriasis, n (%)
Topical agents 34 (91.9) 31 (83.8) 33 (91.7) 64 (87.7) 98 (89.1)
Conventional systemic therapies 16 (43.2) 14 (37.8) 17 (47.2) 31 (42.5) 47 (42.7)
UVB 11 (29.7) 15 (40.5) 13 (36.1) 28 (38.4) 39 (35.5)
Methotrexate 8 (21.6) 8 (21.6) 6 (16.7) 14 (19.2) 22 (20.0)
Biologics 5 (13.5) 4 (10.8) 3 (8.3) 7 (9.6) 12 (10.9)
PUVA 0 3 (8.1) 4 (11.1) 7 (9.6) 7 (6.4)
BSA, Body surface area; PUVA, psoralen with ultraviolet light A; SD, standard deviation; UVB, ultraviolet B.
*Ustekinumab half-standard dosage: 0.375 mg/kg for patients weighing #60 kg, 22.5 mg for patients weighing[60 kg to #100 kg, and
45 mg for patients weighing[100 kg.
yUstekinumab standard dosage: 0.75 mg/kg for patients weighing #60 kg, 45 mg for patients weighing[60 kg to #100 kg, and 90 mg for
patients weighing[100 kg.
Table II. Primary and select secondary endpoints at week 12
Placebo
Ustekinumab
Half-standard dosage* Standard dosagey
Patients randomized, n 37 37 36
PGA 0/1, n (%) 2 (5.4) 25 (67.6)z 25 (69.4)z
PGA 0 1 (2.7) 12 (32.4)z 17 (47.2)z
PASI 75, n (%) 4 (10.8) 29 (78.4)z 29 (80.6)z
PASI 90, n (%) 2 (5.4) 20 (54.1)z 22 (61.1)z
Change from baseline in CDLQI, n 32 35 32
Mean (SD) 1.5 (3.2) 5.6 (6.4)x 6.7 (5.6)z
Patients with CDLQI score 0/1, n (%) 4/30 (13.3) 12/31 (38.7){ 17/30 (56.7)z
SD, Standard deviation.
*Ustekinumab half-standard dosage: 0.375 mg/kg for patients weighing #60 kg, 22.5 mg for patients weighing[60 kg to #100 kg, and
45 mg for patients weighing[100 kg.
yUstekinumab standard dosage: 0.75 mg/kg for patients weighing #60 kg, 45 mg for patients weighing[60 kg to #100 kg, and 90 mg for
patients weighing[100 kg.
zP\ .001 vs placebo.
xP\ .01 vs placebo.
{P\ .05 vs placebo.
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Fig 3. Ustekinumab in adolescent patients with psoriasis. Proportions of patients with a PGA
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Landells et al 599were maintained from week 12 through 52 (Figs 3
and 4). Among placebo patients who crossed over
to ustekinumab at week 12, PASI 75 response
rates increased by week 16 and were maintained
through week 52. The proportions of patients
achieving PGA 0/1, PASI 75, or PASI 90
after crossover were generally similar to those
observed in patients who started ustekinumab at
baseline (Figs 3 and 4). Through week 52, the
proportions of patients with PGA 0/1, PASI 75, or
PASI 90 were numerically greater in the SD group
compared with the HSD group; however, no formal
statistical comparisons were performed (Figs 3
and 4).
HRQoL also improved among ustekinumab-
treated patients through week 12. Mean
changes in CDLQI from baseline were significantly
greater in the HSD (5.6) and SD (6.7)
groups compared with placebo (1.5; P = .003
and P \ .001, respectively) (Table II). Among
patients with CDLQI greater than 1 at baseline,
significantly greater proportions of ustekinumab-
treated patients achieved a CDLQI 0/1 (indicative of
no effect of psoriasis on HRQoL) compared
with placebo (Table II). Mean improvements in
CDLQI were maintained through week 52 in
both the HSD (4.9) and SD (7.6) groups. Atweek 52, CDLQI 0/1 was achieved by 50.0% and
58.6% of patients in the HSD and SD groups,
respectively.
Through week 12, 51.4% of patients in the HSD
group, 44.4% in the SD group, and 56.8% in the
placebo group reported $1 AE (Table III); most
AEs were mild or moderate. In general, AE rates
were similar across treatment groups, and no dose
effect was observed. AEs in the Infections and
Infestations category were the most common
(HSD, 32.4%; SD, 25.0%; placebo, 40.5%); none
was considered serious. Through week 12, the
most common AEs were nasopharyngitis (HSD,
13.5%; SD, 2.8%; placebo, 27.0%) and headache
(HSD, 10.8%; SD, 8.3%; placebo, 5.4%). One
serious AE (SAE; worsening of psoriasis) was
reported in the HSD group.
Through week 40, all 110 patients received $1
injection of ustekinumab; among these, 81.8%
reported an AE through week 60 (Table III).
Infections and Infestations was the most common
category of AEs, with nasopharyngitis (34.5%),
upper respiratory tract infection (12.7%), and
pharyngitis (8.2%) occurring most often. After
week 12, 5 additional singular SAEs were reported
(total, 6; HSD, 5; SD, 1) through week 60. An SAE
of leukopenia, described by the investigator as
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Fig 4. Ustekinumab in adolescent patients with psoriasis. Proportions of patients with a PASI 75
(A, B) or PASI 90 (C, D) response through week 52.
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simplex infection, occurred in one patient (HSD
group). Two serious infections were reported
(pyelonephritis [HSD]; ear infection [SD]). One
patient in the HSD group experienced acute
contact allergic dermatitis caused by hair dye,
and another died in an automobile accident. Ofthe 508 ustekinumab injections, only one was
associated with an injection site reaction;
this mild reaction occurred at baseline in the
SD group. There were no malignancies, active
tuberculosis cases, opportunistic infections,
anaphylactic reactions, or serum sicknesselike
reactions through week 60.
Table III. Adverse events
Adverse events through week 12 (placebo-controlled period)
Placebo
Ustekinumab
Half-standard dosage Standard dosage Combined
Patients, n 37 37 36 73
Mean duration of follow-up, wk 12.2 12.2 12.4 12.3
Mean exposure, wk 4.2 4.2 4.1 4.1
Patients with $1 AE 21 (56.8) 19 (51.4) 16 (44.4) 35 (47.9)
Patients who discontinued due to AE 0 0 0 0
Infections 14 (37.8) 12 (32.4) 8 (22.2) 20 (27.4)
Patients with $1 SAE 0 1 (2.7) 0 1 (1.4)
Serious infections 0 0 0 0
Malignancies 0 0 0 0
Adverse events through week 60
Ustekinumab
Placebo ➝ Half-standard
dosage
Placebo ➝ Standard
dosage
Half-standard
dosage
Standard
dosage Combined
Patients, n 19 18 37 36 110
Mean duration of follow-up, wk 45.9 46.9 55.2 58.0 53.2
Mean exposure, wk 27.3 28.1 38.0 39.0 34.9
Patients with $1 AE 15 (78.9) 13 (72.2) 33 (89.2) 29 (80.6) 90 (81.8)
Patients who discontinued due to AE 2 (10.5) 0 2 (5.4) 0 4 (3.6)
Infections 13 (68.4) 11 (61.1) 26 (70.3) 24 (66.7) 74 (67.3)
Patients with $ 1 SAE 0 0 5 (13.5) 1 (2.8) 6 (5.5)
Serious infections 0 0 1 (2.7) 1 (2.8) 2 (1.8)
Malignancies 0 0 0 0 0
Data presented as n (%) unless otherwise noted.
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Landells et al 601All 110 patients had at least one serum sample
available after ustekinumab treatment for evaluating
antibodies to ustekinumab. Through week 60,
9 (8.2%) patients tested positive for antibodies
to ustekinumab: 6 and 3 in the HSD and SD
groups, respectively. Among these patients, 6
achieved a PGA 0/1 simultaneously to the detection
of antibodies to ustekinumab; therefore, the
presence of antibodies to ustekinumab did not
appear to preclude a clinical response. One of the
patients who tested positive for antibodies to
ustekinumab experienced the single mild injection
site reaction at baseline.
Steady state was achieved at week 28 in both
the HSD and SD groups with no systemic drug
accumulation evident over time. Approximate dose
proportionality in serum ustekinumab concentration
was observed, such that mean concentrations in the
SD group were 1.4-fold to 3.2-fold higher than
those in the HSD group. In each dose group, similar
serum ustekinumab concentrations were observed
between patients weighing #60 kg receiving a
weight-adjusted ustekinumab dose (0.375 mg/kg or
0.75 mg/kg) and those greater than 60 to #100 kg
receiving a fixed ustekinumab dose (22.5 mg or
45 mg). Only 3 patients weighed more than 100 kg atbaseline, making comparisons with this weight
group difficult.
DISCUSSION
CADMUS is the first phase 3, randomized,
placebo-controlled trial of ustekinumab in adoles-
cent patients age 12 to 17 years (inclusive)
with moderate-to-severe plaque psoriasis. Patients
in both the HSD and SD ustekinumab groups
experienced robust and clinically meaningful
improvements in disease activity. Of note, more
than half of ustekinumab-treated patients (HSD,
54.1%; SD, 61.1%) achieved PASI 90 at week 12.
The therapeutic effect of ustekinumab was
observed in a number of patients as early as
week 4. Improvements in HRQoL were also
significantly greater in the ustekinumab groups
compared with the placebo group. Although PGA
0/1 and PASI 75 results were generally comparable
between the HSD and SD groups through week 12,
differences in responses favored the SD for higher
level responses such as PGA 0, PASI 90, and CDLQI
0/1. Beyond week 12, clinical response in the SD
group was generally higher and better sustained
than in the HSD group, in which a modest loss of
response was more frequently observed toward the
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clinical response between the 2 dose groups were
less pronounced through week 12, likely as a result
of the additional loading dose administered at
week 4 in both dose groups. Maximum responses
based on PGA and PASI were achieved by week 12
and maintained through week 52.
Comparisons of clinical response at week 28,
when steady state was achieved, from the
CADMUS trial and the PHOENIX adult ustekinu-
mab studies5,6 showed that the response observed
with the HSD in the CADMUS trial was generally
lower than that seen in adults, whereas response
with the SD was similar to (or higher than) that in
adults. Comparable ustekinumab exposures were
achieved in patients weighing #60 kg with the
milligram to kilogram weight-adjusted dose and in
patients weighing greater than 60 to #100 kg who
received the fixed dose. This suggests that the
0.75-mg/kg dose adjustment implemented in
CADMUS is appropriate for adolescents with a
body weight #60 kg. Moreover, comparing serum
ustekinumab concentrations from this trial and the
previous adult trials suggests that systemic expo-
sure to ustekinumab in adolescent patients (age
$12 years) receiving the body weighteadjusted SD
was comparable to that of adults receiving the
approved psoriasis dosage (data not shown).
Our results also provide information that is
more broadly applicable to adolescent psoriasis
treatment, particularly for therapeutic monoclonal
antibodies. The observation that weight-adjusted
dosing in the pediatric population in CADMUS
resulted in ustekinumab exposure comparable to
that in adults provides additional evidence that the
metabolism of therapeutic monoclonal antibodies
in adolescent patients aged 12 to 17 years is similar
to that in adult patients. The AEs in this trial were
consistent with those previously observed in adult
patients receiving ustekinumab. The challenges to
effective disease management that pediatric
psoriasis patients currently face is highlighted by
the substantial proportion of CADMUS patients
who had not previously received either systemic
treatment or phototherapy, even though they had
relatively severe psoriasis, a major HRQoL issue in
this young population.12
Among the biologic agents approved worldwide
for adult patients with psoriasis, only etanercept and
adalimumab are currently indicated for use in
children and only in Europe. Paller et al13 reported
that 53% of 106 patients (age 4 to 17 years) receiving
weekly etanercept (0.8 mg/kg) achieved PGA 0/1,
57% achieved PASI 75, and 27% achieved PASI 90 at
week 12.Limitations of our study include the relatively
small number of patients, the predominantly
white study population, and the 1-year treatment
duration. That only 3 patients weighed[100 kg at
baseline limits the generalizability of these
findings to heavier children. However, it is
clear the weight-based SD provided exposure
comparable to that in adults with comparable
clinical response and that the lower HSD
provided suboptimal long-term response in this
CADMUS population. The similar ustekinumab
exposure observed in adult patients and
patients 12 to 17 years is reassuring, given the
well-characterized safety profile from the extensive
experience in adult patients.14,15
Our findings suggest a positive benefit-to-risk
profile for ustekinumab treatment of adolescents
with moderate-to-severe psoriasis. A weight-based
dosing strategy achieving exposure similar to
that observed with the current adult dosage
resulted in robust improvements in disease activity
and HRQoL with no unexpected AEs noted.
Ustekinumab appears to provide a beneficial and
convenient treatment option for moderate-to-severe
psoriasis in the pediatric population age 12 years and
older.
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